Literature DB >> 23179573

Impact of treatments for osteoporosis on osteoarthritis progression.

C Roux1, P Richette.   

Abstract

Subchondral bone is involved in the development of osteoarthritis, with an excess in bone resorption at an early stage and increased bone formation thereafter. Experimental and observational studies suggest that acting on bone can change progression of osteoarthritis. Clinical prospective controlled studies failed to confirm this result. Appropriate identification of patients at high risk of developing cartilage deterioration is a key issue for the analysis of impact of treatments for osteoporosis on osteoarthritis progression.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23179573     DOI： 10.1007/s00198-012-2168-6

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


  17 in total

1.  Teriparatide as a chondroregenerative therapy for injury-induced osteoarthritis.

Authors:  Erik R Sampson; Matthew J Hilton; Ye Tian; Di Chen; Edward M Schwarz; Robert A Mooney; Susan V Bukata; Regis J O'Keefe; Hani Awad; J Edward Puzas; Randy N Rosier; Michael J Zuscik
Journal:  Sci Transl Med       Date:  2011-09-21       Impact factor: 17.956

2.  Variability in knee radiographing: implication for definition of radiological progression in medial knee osteoarthritis.

Authors:  P Ravaud; B Giraudeau; G R Auleley; J L Drape; B Rousselin; L Paolozzi; C Chastang; M Dougados
Journal:  Ann Rheum Dis       Date:  1998-10       Impact factor: 19.103

3.  A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients.

Authors:  J C Buckland-Wright; E A Messent; C O Bingham; R J Ward; C Tonkin
Journal:  Rheumatology (Oxford)       Date:  2006-07-11       Impact factor: 7.580

4.  Bone marrow lesions in the knee are associated with increased local bone density.

Authors:  Grace H Lo; David J Hunter; Yuqing Zhang; Christine E McLennan; Michael P Lavalley; Douglas P Kiel; Robert R McLean; Harry K Genant; Ali Guermazi; David T Felson
Journal:  Arthritis Rheum       Date:  2005-09

5.  Markers of bone formation and resorption identify subgroups of patients with clinical knee osteoarthritis who have reduced rates of cartilage loss.

Authors:  Patricia A Berry; Rose A Maciewicz; Flavia M Cicuttini; Mark D Jones; Caroline J Hellawell; Anita E Wluka
Journal:  J Rheumatol       Date:  2010-04-15       Impact factor: 4.666

6.  The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage.

Authors:  C Muehleman; J Green; J M Williams; K E Kuettner; E J-M A Thonar; D R Sumner
Journal:  Osteoarthritis Cartilage       Date:  2002-03       Impact factor: 6.576

7.  Chondroprotective effect of alendronate in a rabbit model of osteoarthritis.

Authors:  Takaaki Shirai; Masahiko Kobayashi; Kohei Nishitani; Tsuyoshi Satake; Hiroshi Kuroki; Yasuaki Nakagawa; Takashi Nakamura
Journal:  J Orthop Res       Date:  2011-04-01       Impact factor: 3.494

8.  The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis.

Authors:  Laura D Carbone; Michael C Nevitt; Kathryn Wildy; Karen D Barrow; Fran Harris; David Felson; Charles Peterfy; Marjolein Visser; Tamara B Harris; Benjamin W E Wang; Stephen B Kritchevsky
Journal:  Arthritis Rheum       Date:  2004-11

9.  Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study.

Authors:  Clifton O Bingham; J Chris Buckland-Wright; Patrick Garnero; Stanley B Cohen; Maxime Dougados; Silvano Adami; Daniel J Clauw; Timothy D Spector; Jean-Pierre Pelletier; Jean-Pierre Raynauld; Vibeke Strand; Lee S Simon; Joan M Meyer; Gary A Cline; John F Beary
Journal:  Arthritis Rheum       Date:  2006-11

10.  Bone marrow edema and its relation to progression of knee osteoarthritis.

Authors:  David T Felson; Sara McLaughlin; Joyce Goggins; Michael P LaValley; M Elon Gale; Saara Totterman; Wei Li; Catherine Hill; Daniel Gale
Journal:  Ann Intern Med       Date:  2003-09-02       Impact factor: 25.391
View more
  6 in total

Review 1.  Osteoarthritis and osteoporosis: what is the overlap?

Authors:  Irene E M Bultink; Willem F Lems
Journal:  Curr Rheumatol Rep       Date:  2013-05       Impact factor: 4.592

Review 2.  Osteoarthritis and bone mineral density: are strong bones bad for joints?

Authors:  Sarah A Hardcastle; Paul Dieppe; Celia L Gregson; George Davey Smith; Jon H Tobias
Journal:  Bonekey Rep       Date:  2015-01-21

3.  A comparative study of Sr-incorporated mesoporous bioactive glass scaffolds for regeneration of osteopenic bone defects.

Authors:  L Wei; J Ke; I Prasadam; R J Miron; S Lin; Y Xiao; J Chang; C Wu; Y Zhang
Journal:  Osteoporos Int       Date:  2014-05-08       Impact factor: 4.507

4.  Chinese herbal prescriptions for osteoarthritis in Taiwan: analysis of National Health Insurance dataset.

Authors:  Fang-Pey Chen; Ching-Mao Chang; Shinn-Jang Hwang; Yu-Chun Chen; Fun-Jou Chen
Journal:  BMC Complement Altern Med       Date:  2014-03-07       Impact factor: 3.659

5.  PLGA scaffold carrying icariin to inhibit the progression of osteoarthritis in rabbits.

Authors:  Chang Fu Zhao; Zhen Hua Li; Shao Jun Li; Jian An Li; Ting Ting Hou; Yang Wang
Journal:  R Soc Open Sci       Date:  2019-04-10       Impact factor: 2.963

6.  BNTA alleviates inflammatory osteolysis by the SOD mediated anti-oxidation and anti-inflammation effect on inhibiting osteoclastogenesis.

Authors:  Huidong Wang; Xiankun Cao; Jiadong Guo; Xiao Yang; Xiaojiang Sun; Zhiyi Fu; An Qin; Yujie Wu; Jie Zhao
Journal:  Front Pharmacol       Date:  2022-09-29       Impact factor: 5.988
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.